Market Overview

FDA Receives Repros' Submission for Special Protocol Assessment Documentation for Pivotal Studies for Androxal


Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced it has received confirmation of delivery of the required documentation for Special Protocol Assessment of its Androxal® Phase 3 pivotal studies to the FDA. Per the Prescription Drug User Fee Act ("PDUFA"), the FDA has 45 calendar days to provide comments back to Repros.

Posted-In: News FDA


Related Articles (RPRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→